Schrödinger to Receive Research Funding and Milestone Payments from ONO

New York, NY － Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, today announced a research collaboration with Ono Pharmaceutical (ONO) to develop novel therapeutics.

Under the terms of the agreement, the companies will work together to leverage Schrödinger’s computational drug discovery platform in the design of novel small molecules to exploit therapeutic targets selected by ONO. Schrödinger will receive research funding plus milestone payments from ONO. Additional details and financial terms of the collaboration were not disclosed.

“We have a high regard for Schrödinger’s computational drug discovery method,” said Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of ONO. “We are excited to work with Schrödinger on identifying and developing the next generation of innovative treatments.”

“Ono has been a long-time user of our software, and we’re very pleased to deepen our engagement with them,” said Ramy Farid, Schrödinger’s President and CEO. “We look forward to continuing to enable Ono’s efforts to design innovative new drugs that promise to have an important impact on the lives of patients.”